DOCSLIB.ORG

Trazodone Is Not As Effective As Other Antidepressants in Treating a Patient with Major Depressive Disorder

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Trazodone Is Not As Effective As Other Antidepressants in Treating a Patient with Major Depressive Disorder Case Report Taiwanese Journal of Psychiatry (Taipei) Vol. 26 No. 4 2012 • 311 • Trazodone Is Not as Effective as Other Antidepressants in Treating a Patient with Major Depressive Disorder Kah Kheng Goh, M.D.1, Weng-Kin Tam, M.D.1, Winston W. Shen, M.D.1, 2* Background: Trazodone in clinical use is ineffective because of its sed ation to let patient receive an adequate dose for treating a patient with major depressive disorder. We are report a case report to demonstrate this clinical effi cacy issue in the treatment with trazodone. Case Report: A 83-year old male Taiwanese patient had suffered from MDD for six months. He did not response to the treatment of trazodone 150 mg/day for four months, but consequently, he responded to the treatment of milnacipran 100 mg/day or mirtazapine 30 mg/day. Conclusion: Psy- chiatrists in Taiwan should be alert to the fact that trazodone is not as effective as other antidepressants, and that trazodone should not be prescribed as a single anti- depressant in treating an MDD patient. Key words: antidepressant therapy, suicide, venlafaxine, bupropion (Taiwanese Journal of Psychiatry [Taipei] 2012; 26: 311-5) guideline in the paragraph in describing individu- Introduction al drug trazodone also indicates “other investiga- tors found trazodone to be less effective than other The practice guideline of the American antidepressant medications” [1]. In this case re- Psychiatric Association in the paragraph of intro- port here, we are reporting a case of a major de- ducing antidepressants states “Although some pressive disorder (MDD) patient, who did not re- studies have suggested superiority of one mecha- spond to daily dose of 150 mg of trazodone, but nism of action over another, there are no replica- responded well to antidepressants 100 mg of mil- ble or robust fi ndings to establish a clinically nacipran per day and maybe 30 mg of mirtazapine meaningful difference. For most patients, the ef- per day consequently. fectiveness of antidepressant medications is gen- erally comparable between classes and within classes of medications” [1]. But the same practice Departments of Psychiatry, Wan Fang Medical Center,1, 2 and School of Medicine,2 Taipei Medical University Received: November 23, 2012; revised: November 26, 2012; accepted: November 26, 2012 *Corresponding author. Department of Psychiatry, TMU-WFMC, 111, Section 3, Shing Long Road, Taiwan 116, Taiwan E-mail: Winston W. Shen <[email protected]> • 312 • Trazodone is an Ineffective Antidepressant then, he was instructed to move up the dose to 100 Case Report mg/day on day 7. At his request, he received es- tazolam 2 mg/day to replace for zolpidem due to An 83-year old male patient had been enjoy- his report of occasional complex behaviors such ing his 17-year retirement life in singing songs at as occasional sleep-walking induced by zolpidem a local karaoke club and making frequent trips un- [2]. He was also instructed to taper off trazodone til eight months previously. When he was seen at by 50 mg every four days, to discontinue estazol- the clinic with his wife in September 2012, he and am 0.5 mg every night, and to continue to take his his wife described his being depressed with severe previous alprazolam 0.5 mg by month t.i.d. At chronic insomnia. He had been treated at a psychi- visit 2 on September 18, two weeks later, the pa- atric clinic at a medical center for more than four tient reported that he had faithfully been taking months with daily trazodone 150 mg, alprazolam medications and had tolerated them well without 1.5 mg and zolpidem 10 mg. He also specifi cally any complaint of side effects except decreased ap- mentioned that he had been taking alprazolam petite, and that he got some appreciable benefi t with the above noted dosage from a non-psychia- especially in the improved insomnia and other trist physician for more than 10 years. MDD symptoms and signs. At visit 4 on October In the mental status examination at clinic 2, another two weeks later, he started to wonder visit 1 on September 4, 2012, the patient presented whether that he could have his milnacipran dis- himself with sad mood, lack of interest, insomnia, continued because of weight loss of 3 kg (from 68 irritability, lack of energy, guilty feeling towards kg to 65 kg) after being on milnacipran for four his wife, inability in concentration, and vague sui- weeks. He was persuaded to stay on milnacipran cidal idea. He was not demented and he denied and he agreed to do so. any delusion and hallucinations. He had stopped At visit 5 on October 11, or day 37 from his singing and travelling in the past six months after fi rst clinic visit here, the patient had showed fur- the onset of his MDD. He had 172 cm in height ther improvement in mood, but still insisted on and 68 kg in weight. He denied any history of ma- having his milnacipran discontinued because he jor operations, drug allergy, or substance abuse. planned to take a sight-seeing gourmet trip to Medical history showed his 20-year history of hy- Japan. As a compromise, we gave him on top of pertension and diabetes mellitus under unknown existing milnacipran 100 mg/day, 30 mg per night oral medications prescribed from a medical clinic of mirtazapine starting three days before his 10- at a different hospital. He reported his depression day trip. At visit 6 on October 24, he came back family history that his sister, four years younger from his 10-day trip, and reported his further im- than the patient, suffered from MDD. She had re- provement under daily combined milnacipran 100 ceived 150 mg/day of trazodone and two benzodi- mg and mirtazapine 30 mg. He also mentioned azepines from our patient’s previous psychiatrist that was pleased to regain his lost body weight of for more than six months, but committed suicide 3 kg. After being offered to have one of two anti- six months previously. depressants discontinued, he chose to stay on mir- At visit 1 on September 4 at the clinic, the tazapine 30 mg/night and stopped taking mil- patient initially received 25 mg/day of milnacip- nacipran after a gradual taper. At visit 7 on ran on days 1-4 and 50 mg/day on days 5 and 6, November 8, he continued to have his remitted Goh KK, Tam WK, Shen WW • 313 • state from MDD, and received a three-week sup- tients. Of interest, a signifi cant proportion of tra- ply of mirtazapine and alprazolam 0.5 mg t.i.d., zodone was prescribed for mood or anxiety disor- with the instruction to taper off alprazolam 0.5 mg ders without having diagnostic code of sleep per week. His body weight stayed at 68 kg. At disorders [3]. In a set of unpublished data consist- visit 8, November 22, he came back for another ing of 1,750 elder patients, most common antide- follow-up. He continued to do well with his pressant received among elderly depressive inpa- weight kept at 68 kg under 30 mg/night of mirlaz- tients in Taiwan is trazodone (19.0%) [4]. In a epine. He had taken only three 0.5 mg of alpra- further analysis, there is no signifi cant difference zolam in the previous 10 days. between the trazodone prescription rate by psy- chiatrists (24.3%) and that by non-psychiatrist Discussion physicians (26.4%) [4]. Our patient did not respond to the treatment The most salient message in this case report of 150 mg/day of trazodone for at least four is that our patient responded readily to milnacip- months, but responded satisfactorily to milnacip- ran and mirtazapine at regularly daily approved ran and consequently to mirtazapine. The ineffi - clinical dose, but he did not respond to the treat- cacy issue of trazodone in this case report is sup- ment of daily trazodone 150 mg for six months. ported by the data from two studies [5, 6]. In a The patient got almost remitted after having re- double-blind, placebo-controlled clinical trial ceived a four-week treatment with 100 mg/day of comparing the effi cacy of trazodone (150-400 mg/ milnacipran. We suspect that he would have be- day) versus venlafaxine (75-200 mg/day), both come remitted completely from MDD if he would active treatments have been found to be signifi - stay on milnacipran without his being bothered by cantly more effective than placebo on some mea- the side effect of 3-kg weight loss, and stay on the sures during the short-term study [5]. But venla- milnacipran treatment. We also speculated that the faxine-treated patients are found to be improved patient might be a potential victim of committing signifi cantly in the scores of both cognitive distur- suicide as his sister did if his suicidal idea would bances (items 2, 3, 19, 20, and 21of the Hamilton become stronger in severity while continuing to Rating Scale for Depression) and retardation fac- receive 150 mg/day of trazodone. tors (items 1, 7, 8, and 14) compared to those The use of antidepressants in Taiwan was in treated with placebo, although trazodone-treated an increased trend from 2000 to 2009, but the patients showed signifi cant improvement in sleep speed of the trend in Taiwan was still lower than disturbances (items 4, 5 and 6) compared to other that in other developed countries [3]. In Taiwan, two study groups [5]. Furthermore, patients on fi ve most frequently prescribed antidepressants venlafaxine were most likely to enter the long- are imipramine, trazodone, melitracen/fl upentix- term phase and to remain in the clinical trial lon- ol, doxepin, and fl uoxetine.
Load more

Recommended publications
  • Schizophrenia Care Guide
    August 2015 CCHCS/DHCS Care Guide: Schizophrenia SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT GOALS ALERTS Minimize frequency and severity of psychotic episodes Suicidal ideation or gestures Encourage medication adherence Abnormal movements Manage medication side effects Delusions Monitor as clinically appropriate Neuroleptic Malignant Syndrome Danger to self or others DIAGNOSTIC CRITERIA/EVALUATION (PER DSM V) 1. Rule out delirium or other medical illnesses mimicking schizophrenia (see page 5), medications or drugs of abuse causing psychosis (see page 6), other mental illness causes of psychosis, e.g., Bipolar Mania or Depression, Major Depression, PTSD, borderline personality disorder (see page 4). Ideas in patients (even odd ideas) that we disagree with can be learned and are therefore not necessarily signs of schizophrenia. Schizophrenia is a world-wide phenomenon that can occur in cultures with widely differing ideas. 2. Diagnosis is made based on the following: (Criteria A and B must be met) A. Two of the following symptoms/signs must be present over much of at least one month (unless treated), with a significant impact on social or occupational functioning, over at least a 6-month period of time: Delusions, Hallucinations, Disorganized Speech, Negative symptoms (social withdrawal, poverty of thought, etc.), severely disorganized or catatonic behavior. B. At least one of the symptoms/signs should be Delusions, Hallucinations, or Disorganized Speech. TREATMENT OPTIONS MEDICATIONS Informed consent for psychotropic
    [Show full text]
  • THE USE of MIRTAZAPINE AS a HYPNOTIC O Uso Da Mirtazapina Como Hipnótico Francisca Magalhães Scoralicka, Einstein Francisco Camargosa, Otávio Toledo Nóbregaa
    ARTIGO ESPECIAL THE USE OF MIRTAZAPINE AS A HYPNOTIC O uso da mirtazapina como hipnótico Francisca Magalhães Scoralicka, Einstein Francisco Camargosa, Otávio Toledo Nóbregaa Prescription of approved hypnotics for insomnia decreased by more than 50%, whereas of antidepressive agents outstripped that of hypnotics. However, there is little data on their efficacy to treat insomnia, and many of these medications may be associated with known side effects. Antidepressants are associated with various effects on sleep patterns, depending on the intrinsic pharmacological properties of the active agent, such as degree of inhibition of serotonin or noradrenaline reuptake, effects on 5-HT1A and 5-HT2 receptors, action(s) at alpha-adrenoceptors, and/or histamine H1 sites. Mirtazapine is a noradrenergic and specific serotonergic antidepressive agent that acts by antagonizing alpha-2 adrenergic receptors and blocking 5-HT2 and 5-HT3 receptors. It has high affinity for histamine H1 receptors, low affinity for dopaminergic receptors, and lacks anticholinergic activity. In spite of these potential beneficial effects of mirtazapine on sleep, no placebo-controlled randomized clinical trials of ABSTRACT mirtazapine in primary insomniacs have been conducted. Mirtazapine was associated with improvements in sleep on normal sleepers and depressed patients. The most common side effects of mirtazapine, i.e. dry mouth, drowsiness, increased appetite and increased body weight, were mostly mild and transient. Considering its use in elderly people, this paper provides a revision about studies regarding mirtazapine for sleep disorders. KEYWORDS: sleep; antidepressive agents; sleep disorders; treatment� A prescrição de hipnóticos aprovados para insônia diminuiu em mais de 50%, enquanto de antidepressivos ultrapassou a dos primeiros.
    [Show full text]
  • Deanxit SPC.Pdf
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Deanxit film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Flupentixol 0.5 mg (as 0.584 mg flupentixol dihydrochloride) Melitracen 10 mg (as 11.25 mg melitracen hydrochloride) Excipients with known effect: Lactose monohydrate For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablets. Round, biconvex, cyclamen, film-coated tablets. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Anxiety Depression Asthenia. Neurasthenia. Psychogenic depression. Depressive neuroses. Masked depression. Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions. Dysphoria and depression in alcoholics and drug-addicts. 4.2 Posology and method of administration Posology Adults Usually 2 tablets daily: morning and noon. In severe cases the morning dose may be increased to 2 tablets. The maximum dose is 4 tablets daily. Older people (> 65 years) 1 tablet in the morning. In severe cases 1 tablet in the morning and 1 at noon. Maintenance dose: Usually 1 tablet in the morning. SPC Portrait-REG_00051968 20v038 Page 1 of 10 In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended. Paediatric population Children and adolescents (<18 years) Deanxit is not recommended for use in children and adolescents due to lack of data on safety and efficacy. Reduced renal function Deanxit can be given in the recommended doses. Reduced liver function Deanxit can be given in the recommended doses. Method of administration The tablets are swallowed with water. 4.3 Contraindications Hypersensitivity to flupentixol and melitracen or to any of the excipients listed in section 6.1.
    [Show full text]
  • Repeated Lysergic Acid Diethylamide in an Animal Model of Depression
    JOP0010.1177/0269881114531666Journal of PsychopharmacologyBuchborn et al. 531666research-article2014 Original Paper Repeated lysergic acid diethylamide in an animal model of depression: Normalisation of learning behaviour and Journal of Psychopharmacology 2014, Vol. 28(6) 545 –552 hippocampal serotonin 5-HT signalling © The Author(s) 2014 2 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0269881114531666 jop.sagepub.com Tobias Buchborn, Helmut Schröder, Volker Höllt and Gisela Grecksch Abstract A re-balance of postsynaptic serotonin (5-HT) receptor signalling, with an increase in 5-HT1A and a decrease in 5-HT2A signalling, is a final common pathway multiple antidepressants share. Given that the 5-HT1A/2A agonist lysergic acid diethylamide (LSD), when repeatedly applied, selectively downregulates 5-HT2A, but not 5-HT1A receptors, one might expect LSD to similarly re-balance the postsynaptic 5-HT signalling. Challenging this idea, we use an animal model of depression specifically responding to repeated antidepressant treatment (olfactory bulbectomy), and test the antidepressant-like properties of repeated LSD treatment (0.13 mg/kg/d, 11 d). In line with former findings, we observe that bulbectomised rats show marked deficits in active avoidance learning. These deficits, similarly as we earlier noted with imipramine, are largely reversed by repeated LSD administration. Additionally, bulbectomised rats exhibit distinct anomalies of monoamine receptor signalling in hippocampus and/or frontal cortex; 35 from these, only the hippocampal decrease in 5-HT2 related [ S]-GTP-gamma-S binding is normalised by LSD. Importantly, the sham-operated rats do not profit from LSD, and exhibit reduced hippocampal 5-HT2 signalling. As behavioural deficits after bulbectomy respond to agents classified as antidepressants only, we conclude that the effect of LSD in this model can be considered antidepressant-like, and discuss it in terms of a re-balance of hippocampal 5-HT2/5-HT1A signalling.
    [Show full text]
  • Medication: Trazodone (Desyrel) 50 Mg
    Trazodone COMPLEX CHRONIC DISEASES PROGRAM Medication Handout Date: May 15, 2018 Medication: Trazodone 50 mg What is trazodone: Trazodone is an antidepressant that is now used for insomnia; it helps with both falling asleep and staying asleep. Expected Benefit: As a sleep aid, you should notice a benefit on the first night within about 30 minutes of taking the medication. Watch for possible side effects: This list of side effects is important for you to be aware of however, it is also important to remember that not all side effects happen to everyone. If you have problems with these side effects talk with your doctor or pharmacist: Hangover effect (drowsiness that continues after waking up in the morning) Dizziness Dry mouth Headache Nausea Stopping the medication: Stopping trazodone is not usually a problem as there is no withdrawal effect you are taking it regularly at higher doses than prescribed below. Please ask your doctor or pharmacist before stopping the medication. Rebound insomnia is not usually a problem which makes trazodone a good option for taking a sleeping aid as needed How to use this medication: Take this medication with or without food Dosing Schedule: Start with 12.5 mg (¼ tablet) or 25 mg (½ tablet) at bedtime Increase the dose by ¼ or ½ a tablet every night until: o You can fall asleep, and/or o Stay asleep The usual effective dose is 50 – 150 mg at bedtime (1 – 3 tablets) Do not continue increasing the dose if you experience a hangover effect Talk with your doctor if you are still having problems with sleep, as you may need a different medication.
    [Show full text]
  • Depression in the Prime of Life —Its Characteristics and Precautions —Required in Treatment—
    ⅥDepression Depression in the Prime of Life —Its Characteristics and Precautions —Required in Treatment— JMAJ 44(5): 221–224, 2001 Tetsuya HIROSE Professor, Department of Psychiatry, Teikyo University School of Medicine Abstract: Depression may occur at any age, but that occurring in the prime of life (maturity) is considered most typical, given its symptoms, course, and other aspects of serving as a prototypic model. The 3 major depressive symptoms of depressive mood, retardation, and anxiety are often observed to the same extent, demon- strating a stable cycle in mature depression. Attention should be paid, however, to the onset of hypomania because some patients end up as rapid cyclers alternately repeating manic and depressive episodes. This disease often occurs in those with melancholic personality who are scrupulous and have a strong sense of obligation and responsibility when encountering change such as career changes, or may often occur in postpartum depression. Even though endocrine changes should be consid- ered in the latter, it is helpful to handle these cases as attributable to the entangle- ment of character and circumstance. Pharmacotherapy is most effective against depression in this generation. Unlike elderly patients, serious adverse reactions rarely occur, but, it is essential to administer sufficient tricyclic antidepressants, etc., for a long enough time. Mood stabilizers are also required in the treatment of bipolar II disorder. Key words: Mature depression; Typical symptoms; Melancholic personality; Antidepressants; Hypomanic state Introduction often occurs for the first time in those in their late 20s to 30s. Depression is thus considered While schizophrenia is regarded as a disease as a disease typically occurring in the prime of of adolescence, depression is characterized by life.
    [Show full text]
  • Psychotropic Medication Concerns When Treating Individuals with Developmental Disabilities
    Tuesday, 2:30 – 4:00, C2 Psychotropic Medication Concerns when Treating Individuals with Developmental Disabilities Richard Berchou 248-613-6716 [email protected] Objective: Identify effective methods for the practical application of concepts related to improving the delivery of services for persons with developmental disabilities Notes: Medication Assistance On-Line Resources OBTAINING MEDICATION: • Needy Meds o Needymeds.com • Partnership for Prescriptions Assistance o Pparx.org • Patient Assistance Program Center o Rxassist.org • Insurance coverage & Prior authorization forms for most drug plans o Covermymeds.com REMINDERS TO TAKE MEDICATION: • Medication reminder by Email, Phone call, or Text message o Sugaredspoon.com ANSWER MOST QUESTIONS ABOUT MEDICATIONS: • Univ. of Michigan/West Virginia Schools of Pharmacy o Justaskblue.com • Interactions between medications, over-the-counter (OTC) products and some foods; also has a pictorial Pill Identifier: May input an entire list of medications o Drugs.com OTHER TRUSTED SITES: • Patient friendly information about disease and diagnoses o Mayoclinic.com, familydoctor.org • Package inserts, boxed warnings, “Dear Doctor” letters (can sign up to receive e- mail alerts) o Dailymed.nlm.nih.gov • Communications about drug safety o www.Fda.gov/cder/drug/drugsafety/drugindex.htm • Purchasing medications on-line o Pharnacychecker.com Updated 2013 Psychotropic Medication for Persons with Developmental Disabilities April 23, 2013 Richard Berchou, Pharm. D. Assoc. Clinical Prof., Dept. Psychiatry & Behavioral
    [Show full text]
  • Flupentixol 0.5 Mg & Melitracen 10 Mg Tablet
    Flupentixol 0.5 mg & Melitracen 10 mg Tablet COMPOSITION Each film coated tablet contains Flupentixol hydrochloride BP equivalent to 0.5 mg Flupentixol and Melitracen hydrochloride INN equivalent to 10 mg Melitracen. PHARMACOKINETICS Maximum serum concentration is reached in about 4 hours after oral administration of Flupentixol and Melitracen. The half-life of Flupentixol is about 35 hours and that of Melitracen is about 19 hours. The combination of Flupentixol and Melitracen does not seem to influence the pharmacokinetic properties of the individual compounds. INDICATION Psychogenic depression, Depressive neurosis, Psychosomatic affections accompanied by anxiety and apathy, menopausal depression, depression in alcoholics and drug-addicts. DOSAGE AND ADMINISTRATION Adults : Usually 2 tablets daily, in morning and afternoon. In severe cases, the morning dose may be increased to 2 tablets. Elderly patients : 1 tablet in the morning. Maintenance dose : Usually 1 tablet in the morning or as directed by the physician. CONTRAINDICATION It is contraindicated in the immediate recovery phase after myocardial infarction, defects in bundle-branch conduction, untreated narrow angle glaucoma and in acute alcohol, barbiturate & opioid intoxications. Not recommended for excitable patients since its activating effect may lead to exaggeration of these characteristics. SIDE EFFECT In the recommended doses, side effects are rare. These could be transient restlessness and insomnia. PRECAUTION If previously the patient has been treated with tranquilizers with sedative effect these should be withdrawn gradually. DRUG INTERACTION This preparation may enhance the response to alcohol, barbiturates and other CNS depressants. Simultaneous administrantion of MAO-inhibitors may cause hypertensive crisis. USE IN PREGNANCY AND LACTATION The safety of this drug has not been established in pregnancy and lactation.
    [Show full text]
  • Trazodone Hydrochloride, Choline Physician Therapeutics
    TRAZAMINE - trazodone hydrochloride, choline Physician Therapeutics LLC Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. ---------- Trazamine Trazodone Generic Name: Trazodone hydrochloride Dosage Form: tablet Trazodone HYDROCHLORIDE TABLETS, USP Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of Trazodone HCl or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Trazodone HCl is not approved for use in pediatric patients. (See Warnings: Clinical Worsening and Suicide Risk, Precautions: Information for Patients, and Precautions: Pediatric Use Trazodone Description Trazodone HCl is an antidepressant chemically unrelated to tricyclic, tetracyclic, or other known antidepressant agents. Trazodone HCl is a triazolopyridine derivative designated as 2-[3-[4-(m- Chlorophenyl)-1-piperazinyl]propyl]s-triazolo[4,3-a]-pyridin-3 (2H)-one monohydrochloride.
    [Show full text]
  • CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (Also Belong to Psychiatric Medication Category) • Codeine (In 222® Tablets, Tylenol® No
    CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (also belong to psychiatric medication category) • codeine (in 222® Tablets, Tylenol® No. 1/2/3/4, Fiorinal® C, Benzodiazepines Codeine Contin, etc.) • heroin • alprazolam (Xanax®) • hydrocodone (Hycodan®, etc.) • chlordiazepoxide (Librium®) • hydromorphone (Dilaudid®) • clonazepam (Rivotril®) • methadone • diazepam (Valium®) • morphine (MS Contin®, M-Eslon®, Kadian®, Statex®, etc.) • flurazepam (Dalmane®) • oxycodone (in Oxycocet®, Percocet®, Percodan®, OxyContin®, etc.) • lorazepam (Ativan®) • pentazocine (Talwin®) • nitrazepam (Mogadon®) • oxazepam ( Serax®) Alcohol • temazepam (Restoril®) Inhalants Barbiturates • gases (e.g. nitrous oxide, “laughing gas”, chloroform, halothane, • butalbital (in Fiorinal®) ether) • secobarbital (Seconal®) • volatile solvents (benzene, toluene, xylene, acetone, naptha and hexane) Buspirone (Buspar®) • nitrites (amyl nitrite, butyl nitrite and cyclohexyl nitrite – also known as “poppers”) Non-Benzodiazepine Hypnotics (also belong to psychiatric medication category) • chloral hydrate • zopiclone (Imovane®) Other • GHB (gamma-hydroxybutyrate) • Rohypnol (flunitrazepam) CENTRAL NERVOUS SYSTEM STIMULANTS Amphetamines Caffeine • dextroamphetamine (Dexadrine®) Methelynedioxyamphetamine (MDA) • methamphetamine (“Crystal meth”) (also has hallucinogenic actions) • methylphenidate (Biphentin®, Concerta®, Ritalin®) • mixed amphetamine salts (Adderall XR®) 3,4-Methelynedioxymethamphetamine (MDMA, Ecstasy) (also has hallucinogenic actions) Cocaine/Crack
    [Show full text]
  • 1 Supplemental Figure 1: Illustration of Time-Varying
    Supplemental Material Table of Contents Supplemental Table 1: List of classes and medications. Supplemental Table 2: Association between benzodiazepines and mortality in patients initiating hemodialysis (n=69,368) between 2013‐2014 stratified by age, sex, race, and opioid co‐dispensing. Supplemental Figure 1: Illustration of time‐varying exposure to benzodiazepine or opioid claims for one person. Several sensitivity analyses were performed wherein person‐day exposure was extended to +7 days, +14 days, and +28 days beyond the outlined periods above. 1 Supplemental Table 1: List of classes and medications. Class Medications Short‐acting benzodiazepines Alprazolam, estazolam, lorazepam, midazolam, oxazepam, temazepam, and triazolam Long‐acting benzodiazepines chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, flurazepam Opioids alfentanil, buprenorphine, butorphanol, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphine, meperidine, methadone, morphine, nalbuphine, nucynta, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanil, sufentanil, tapentadol, talwin, tramadol, carfentanil, pethidine, and etorphine Antidepressants citalopram, escitalopram, fluoxetine, fluvozamine, paroxetine, sertraline; desvenlafaxine, duloxetine, levomilnacipran, milnacipran, venlafaxine; vilazodone, vortioxetine; nefazodone, trazodone; atomoxetine, reboxetine, teniloxazine, viloxazine; bupropion; amitriptyline, amitriptylinoxide, clomipramine, desipramine, dibenzepin, dimetacrine, dosulepin, doxepin, imipramine, lofepramine, melitracen,
    [Show full text]
  • Currently Prescribed Psychotropic Medications
    CURRENTLY PRESCRIBED PSYCHOTROPIC MEDICATIONS Schizophrenia Depression Anxiety Disorders 1st generation antipsychotics: Tricyclics: Atarax (hydroxyzine) Haldol (haloperidol), *Anafranil (clomipramine) Ativan (lorazepam) Haldol Decanoate Asendin (amoxapine) BuSpar (buspirone) Loxitane (loxapine) Elavil (amitriptyline) *Inderal (propranolol) Mellaril (thioridazine) Norpramin (desipramine) Keppra (levetiracetam) Navane (thiothixene) Pamelor (nortriptyline) *Klonopin (clonazepam) Prolixin (fluphenazine), Prolixin Sinequan (doxepin) Librium (chlordiazepoxide) Decanoate Spravato (esketamine) Serax (oxazepam) Stelazine (trifluoperazine) Surmontil (trimipramine) Thorazine (chlorpromazine) *Tenormin (atenolol) Tofranil (imipramine) MEDICATIONS PSYCHOTROPIC PRESCRIBED CURRENTLY Trilafon (perphenazine) Tranxene (clorazepate) Vivactil (protriptyline) Valium (diazepam) 2nd generation antipsychotics: Zulresso (brexanolone) Vistaril (hydroxyzine) Abilify (aripiprazole) Aristada (aripiprazole) SSRIs: Xanax (alprazolam) Caplyta (lumateperone) Celexa (citalopram) *Antidepressants, especially SSRIs, are also used in the treatment of anxiety. Clozaril (clozapine) Lexapro (escitalopram) Fanapt (iloperidone) *Luvox (fluvoxamine) Geodon (ziprasidone) Paxil (paroxetine) Stimulants (used in the treatment of ADD/ADHD) Invega (paliperidone) Prozac (fluoxetine) Invega Sustenna Zoloft (sertraline) Adderall (amphetamine and Perseris (Risperidone injectable) dextroamphetamine) Latuda (lurasidone) MAOIs: Azstarys(dexmethylphenidate Rexulti (brexpiprazole) Emsam (selegiline)
    [Show full text]